WORLD 2026 Data De-Risk Sangamo’s Fabry Gene Therapy, Supporting Accelerated Approval Path and Long-Term Buy Thesis

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Sangamo Biosciences, retaining the price target of $10.00.

Patrick Trucchio has given his Buy rating due to a combination of factors tied to Sangamo’s Fabry gene therapy program, isa-vec, which he views as a differentiated, disease-modifying treatment with a de-risked regulatory path. He highlights that the latest WORLD 2026 renal, cardiac, pharmacology, and durability data from the Phase 1/2 STAAR registrational trial strongly support the FDA-aligned Accelerated Approval strategy based on eGFR slope and reinforce the overall strength of the clinical package as the rolling BLA advances.

He also notes that the breadth and consistency of multi‑organ benefits, including sustained α‑Gal A expression and favorable long‑term safety and durability signals, enhance confidence in both approval timing and real‑world uptake. With Fabry positioned as the key near‑term value driver and commercialization discussions progressing in parallel, he believes the WORLD 2026 update marks a critical inflection point that underpins his conviction in long‑term value creation and justifies reiterating a Buy rating and $10 price target.